Related posts
BoC cuts again, but markets flatStocks slide on hawkish Fed commentsMarkets pause, awaiting earningsThis summary was created by AI, based on 12 opinions in the last 12 months.
MDLZ has garnered mixed reviews from various experts. Concerns about the impact of GLP-1 drugs on the food industry loom large, with many analysts highlighting a sluggish growth outlook. While the stock has a fair forward P/E valuation around 18.8x, experts note the company's low growth potential with earnings growth expected to remain in the mid-single digits. Additionally, international exposure presents challenges due to a strong USD, and rising cocoa prices are adding cost pressures. Despite these headwinds, some analysts appreciate the company's strong brand position and dividend stability, indicating a preference for long-term hold while acknowledging a lack of significant excitement in the growth aspect of the business.
Trades at 18x PE, with 5% growth. He likes growth at a reasonable price, so 5% doesn't cut it. Stock's moved below 200-day MA, which is falling. Short-term technicals look weak. Demand for GLP-1 drugs will impact a lot of companies in the food business.
Limited private-label competition. During pandemic, good at passing cost increases along to consumers without demand falling off. Concerns about impact of weight-loss drugs has abated. But huge increase in cocoa prices, at 47-year highs. Still happy to own.
It is a large consumer products company and has gone though re-structuring. Pays a rock solid dividend. Although high quality it is low growth so he sees better better value in the field.
International snack giant. 200-day MA is sideways to slightly negative, stock price is now below it. Fundamentals show only mid-single-digit earnings growth, paying 20x for it. Cost pressures, margin compression. Intense competition. Foreign currency has not helped.
For a consumer staples name, look at Loblaw or COST.
Owns shares and would recommend buying. Global consumer goods powerhouse. Strong brand names with sticky adoption rates. Ability to generate profits despite higher chocolate prices. Would recommend holding for the long term. Ability to pass on rising costs to consumers.
Still likes it. Concern now is that with higher interest rates and rising unemployment, consumers are being more price-conscious. Company has acknowledged this in its biscuit category.
Reassessing pricing and packaging. EMs are about 40% of sales, she sees higher growth there. Selling assets, redeploying proceeds in higher-growth adjacent categories.
Nothing much has changed in MDLZ’s fundamentals over the years, except the valuation has gone down and it is now trading at 18.8x times' Forward P/E ( a fair valuation given MDLZ consistently has traded above 20x). The leverage level has gone down meaningfully in recent years, and the net debt/EBITDA level is now at 1.9x, the lowest in years, indicating a capacity for raising dividends or buying back shares. The company has been a predictable grower, and we think MDLZ would be comfortable to grow 3%-5% for a very long time, it is an attractive dividend grower over time, but the business is mature and fairly low growth overall. We would be OK owning it for income but otherwise do not see it as overly interesting.
Unlock Premium - Try 5i Free
Good company, but now up against weight-loss drugs. Makes the core thesis tough. High cocoa prices increased input prices. Lots of international sales, so a strong USD is not constructive.
At the time of this pick, GLP weight-loss drugs were creating overhang on the stock. Very well run. Great presence internationally. Recent quarter underwhelming, lower-income US consumer starting to get pressured. Happy to hold due to market dominance and attractive valuation.
A leader in biscuits and chocolate, with very little private label competition. Very strong brand loyalty. Innovating and acquiring. Disposing of lower-growth areas such as gum. Likes the topline growth, as well as incremental margin growth. Decent yield of 2.4%.
(Analysts’ price target is $83.44)Return on capital inconsistent and low. Free cash flow also not too high. Insider ownership also unclear. Food and beverage hard to compete with if company has a strong moat. Unclear on future of business. Better options for investors in the markets.
Owns shares and believes in prospects of business. Chocolate business very strong. "Snack business" also growing at high rate. Able to pass on costs to consumers. Brand loyalty continues to grown. Strong array of products. Stable business that is good for defensive investors.
Owns a lot of products that don't make money, no return on capital, so needs to rationalize its products. Own these companies now, because you'll reap from the fruition of these efforts. May be some volatility.
Have pricing power, passing higher prices to consumers. Are rapidly growing in emerging markets like Africa. It yields 2.4% now and grows its dividend at 13% compounded over the last decade. It's highly defensive, boasting strong brands like Cadbury.
(Analysts’ price target is $79.05)MONDELEZ INTERNATIONAL INC Common Stock is a American stock, trading under the symbol MDLZ-Q on the NASDAQ (MDLZ). It is usually referred to as NASDAQ:MDLZ or MDLZ-Q
In the last year, 10 stock analysts published opinions about MDLZ-Q. 4 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for MONDELEZ INTERNATIONAL INC Common Stock.
MONDELEZ INTERNATIONAL INC Common Stock was recommended as a Top Pick by on . Read the latest stock experts ratings for MONDELEZ INTERNATIONAL INC Common Stock.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
10 stock analysts on Stockchase covered MONDELEZ INTERNATIONAL INC Common Stock In the last year. It is a trending stock that is worth watching.
On 2025-02-11, MONDELEZ INTERNATIONAL INC Common Stock (MDLZ-Q) stock closed at a price of $59.58.
These companies have traded off on the fears of GLP-1. Volumes starting to drop. Growth metrics just don't support the valuations in the space. About 60% of revenue from international sources, so strong USD is a major headwind.